Furthermore, the parallel presentation of both MHC Class I and II antigens facilitates a stronger overall anti-tumor response and long-term CD8+ T cell memory via CD4+ T cells12, and this anti-tumor response may be further augmented via the specific modification of the vaccine. This evidence concerns the gene CD8A and neoplasm.